Tricuspid regurgitation (TR) is a common cardiac valve disease in clinic. Traditional medical treatment can only relieve symptoms, while surgical operations, due to their large trauma and high risks, are difficult to cover high-risk patients who are elderly and with multiple comorbidities. Transcatheter tricuspid valve intervention (TTVI), as a new treatment strategy, provides a new choice for this group. In recent years, various devices for TTVI have emerged. This paper elaborates the characteristics of TR, the design characteristics of existing TTVI devices, relevant clinical research, and the comprehensive evaluation means of device selection, and points out the existing shortcomings and future development direction.
